pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
tigecycline eql pharma 50 mg infuusiokuiva-aine, liuosta varten
eql pharma ab - tigecycline - infuusiokuiva-aine, liuosta varten - 50 mg - tigesykliini